Astrazeneca
Clinical trials sponsored by Astrazeneca, explained in plain language.
-
New inhaler combo aims to cut teen asthma attacks
Disease control Recruiting nowThis study is testing whether a combination inhaler (budesonide/albuterol) works better than a standard albuterol inhaler when used as needed to prevent severe asthma attacks. It involves 440 teenagers aged 12-18 who have asthma and have had at least one serious attack in the pas…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 19:56 UTC
-
New drug combo aims to protect failing kidneys
Disease control Recruiting nowThis study is testing whether adding a new drug called zibotentan to an existing kidney drug (dapagliflozin) works better than dapagliflozin alone. It aims to see if the combination can better reduce the amount of protein leaking into the urine, which is a sign of kidney damage. …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 19:56 UTC
-
New Triple-Threat treatment enters final testing for Tough-to-Treat breast cancer
Disease control Recruiting nowThis study is testing whether adding a new drug called capivasertib to two standard breast cancer drugs works better for controlling advanced breast cancer. It will involve about 895 adults whose cancer is hormone receptor-positive, HER2-negative, and has worsened despite prior h…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 19:56 UTC
-
Global race for better bile duct cancer treatment
Disease control Recruiting nowThis large global study is comparing two different immunotherapy drugs (rilvegostomig and durvalumab) when combined with standard chemotherapy for people with advanced bile duct cancer who haven't had previous treatment. The main goal is to see which combination helps patients li…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 19:56 UTC
-
New bladder cancer treatment combo tested in global trial
Disease control Recruiting nowThis study is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder removal surgery helps control muscle-invasive bladder cancer better. The research involves 150 patients worldwide who are scheduled for bladder removal surgery…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Radioactive drug trial offers new hope for advanced prostate cancer
Disease control Recruiting nowThis is a first-in-human study testing a new radioactive drug called AZD2284 in men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The main goal is to find a safe and tolerable dose. Researchers will also use imaging to see how t…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope for advanced lung cancer patients in combination therapy trial
Disease control Recruiting nowThis study is testing several new drug combinations for people with advanced or metastatic non-small cell lung cancer. Researchers want to find safe doses and see if these combinations can shrink tumors and help patients live longer. The trial will involve 152 participants and in…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Looking back at cancer drugs: do they work in the real world?
Disease control Recruiting nowThis study is looking back at the medical records of 150 Chinese adults with a specific type of advanced kidney cancer. The goal is to see how well two existing drugs, sunitinib and sorafenib, worked to control the cancer and keep it from getting worse when used as a first treatm…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for aggressive lymphoma: experimental drug combo enters spanish trial
Disease control Recruiting nowThis study is testing whether adding the drug acalabrutinib to standard R-CHOP chemotherapy works better for people newly diagnosed with mantle cell lymphoma. The trial will enroll about 55 adults in Spain who haven't had prior cancer treatments and aren't candidates for stem cel…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Major trial tests if new inhaler combo can protect COPD Patients' hearts and lungs
Disease control Recruiting nowThis large study aims to see if a three-drug inhaler is better than a two-drug inhaler at preventing serious heart and lung problems in people with COPD who are at higher risk for these events. It will involve about 5,000 adults with COPD and certain heart disease risk factors. P…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo tested for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing an experimental drug called trastuzumab deruxtecan (T-DXd), either alone or combined with other cancer drugs, for people with advanced solid tumors that have a specific marker called HER2. The goal is to see if the treatment can shrink tumors and control the…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Race against time: can new drug rescue kidneys from sepsis?
Disease control Recruiting nowThis study is testing whether an experimental drug called AZD4144 can help improve kidney function in hospitalized adults whose kidneys have been injured by a severe bloodstream infection (sepsis). About 124 participants will be randomly assigned to receive either the drug or a p…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug cocktails aim to shrink lung tumors before surgery and keep cancer at bay after
Disease control Recruiting nowThis study is testing several new combinations of immunotherapy and chemotherapy drugs for people with early-stage, operable lung cancer. The goal is to see if giving these drugs before surgery (to shrink the tumor) and after surgery (to prevent the cancer from coming back) is sa…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Tracking a promising lung cancer drug in everyday spanish hospitals
Disease control Recruiting nowThis study aims to understand how well the lung cancer drug osimertinib works for patients in real-world Spanish hospitals, outside of controlled clinical trials. It will follow 500 adults with a specific genetic type of non-small cell lung cancer who are already being treated wi…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New Immune-Boosting drug enters human trials for tough cancers
Disease control Recruiting nowThis early-stage study aims to find a safe and effective dose of a new drug called AZD6750, which is designed to boost the immune system to fight cancer. It will test the drug alone and combined with other cancer treatments in about 60 adults with advanced or spreading solid tumo…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
First test of new drug for autoimmune diseases begins
Disease control Recruiting nowThis is the first study in people to test a new drug called surovatamig for rheumatoid arthritis and lupus. The main goal is to check its safety and how the body processes it in 48 adults with these conditions. Researchers will give the drug as an injection under the skin at diff…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New shot tested to tame severe asthma in kids
Disease control Recruiting nowThis study is testing an injectable medication called tezepelumab in children aged 5 to 12 with severe asthma that is not well-controlled by their current medications. Over 200 children will receive either the drug or a placebo injection for one year to see if it safely reduces s…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New pill aims to tackle bad cholesterol in heart health trial
Disease control Recruiting nowThis study is testing if a new oral drug, AZD0780, can help lower 'bad' cholesterol (LDL-C) in adults who already have high cholesterol. About 76 participants in Russia will take either the new drug or a placebo (a dummy pill) for 12 weeks, in addition to their standard cholester…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for tough stomach cancers: major trial tests targeted therapy
Disease control Recruiting nowThis study is testing a new drug called AZD0901 for people with advanced stomach or gastroesophageal cancer that has spread and stopped responding to initial treatments. It compares AZD0901 to the doctor's choice of standard therapies to see which works better at controlling the …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Major trial aims to delay prostate cancer progression in 1,800 men
Disease control Recruiting nowThis large, late-stage study is testing whether adding an experimental drug called saruparib to standard hormone therapy helps men with metastatic prostate cancer that still responds to hormone treatment. About 1,800 participants will be randomly assigned to receive either the ne…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Tracking a new Treatment's Real-World impact on nasal polyps and asthma
Disease control Recruiting nowThis study aims to see how well the drug tezepelumab works for adults with chronic nasal polyps, with or without asthma, in real-world medical settings. It will follow 110 participants in Russia for about a year to measure changes in their nasal symptoms, asthma control, and over…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug trial aims to tame dangerous lung infections
Disease control Recruiting nowThis study is testing an investigational antibody drug called AZD0292 to see if it can prevent serious lung flare-ups in people with bronchiectasis who have a chronic infection with a bacteria called Pseudomonas aeruginosa. Researchers will compare the drug against a placebo in a…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Major trial launches for Tough-to-Treat bile duct cancer
Disease control Recruiting nowThis study is testing whether two new drug combinations work better than the current standard treatment for advanced bile duct cancer. It will enroll about 620 adults with a specific protein marker (HER2) on their cancer cells who haven't had prior treatment for their advanced di…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Tracking 1000 patients: how well does this asthma treatment work in real life?
Disease control Recruiting nowThis study aims to understand how well the asthma medication benralizumab works for people with severe eosinophilic asthma in everyday clinical practice in China. Researchers will follow 1,000 patients aged 12 and older to see how their asthma control and lung function change ove…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New pill aims to stop deadly prostate cancer spread in High-Risk men
Disease control Recruiting nowThis study is testing if adding a new drug called Saruparib to standard radiation and hormone therapy can better prevent cancer from spreading in men with high-risk prostate cancer who have a specific genetic mutation (BRCA). About 700 men will be randomly assigned to receive eit…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for advanced lung cancer patients in global drug trial
Disease control Recruiting nowThis study is testing several new combinations of cancer drugs for people with advanced non-small cell lung cancer that has spread. The main goals are to see if these combinations are safe and if they can shrink tumors. The trial will involve about 278 patients across 80 medical …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New weapon tested in fight against advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called AZD8205, both by itself and combined with other cancer drugs, for people with advanced solid tumors that have spread or returned. The main goals are to find safe doses and see if the treatments can shrink tumors. It is enrolling…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New weapon unleashed: immune cells reprogrammed to hunt down tough blood cancers
Disease control Recruiting nowThis study is testing a new drug called AZD5492 for adults whose B-cell cancers have come back or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug helps control the cancer. The drug works by directing the patient's own immune T…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:38 UTC
-
New hope drug enters human testing for advanced prostate cancer
Disease control Recruiting nowThis early-stage study is testing a new drug called AZD0516 for men with advanced prostate cancer that has spread. Researchers want to find the safest dose and see if the drug, given alone or with other cancer treatments, can help control the disease. The study will involve about…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Shorter, gentler treatment tested for frail lymphoma patients
Disease control Recruiting nowThis study is testing if a new treatment plan is better for older or frail adults with a type of blood cancer called large B-cell lymphoma. It compares a shorter course of standard chemotherapy followed by a new drug (AZD0486) against a longer course of standard chemotherapy alon…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Major trial tests promising new drug against Tough-to-Treat ovarian cancer
Disease control Recruiting nowThis large Phase 3 trial is testing whether a new drug called AZD5335 works better than current standard treatments for women with advanced ovarian cancer that has stopped responding to platinum chemotherapy. About 1100 participants will be assigned to receive either the new drug…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug combo trial offers hope for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing a new drug called volrustomig, both by itself and combined with chemotherapy, for people with advanced solid tumors that have spread. It is enrolling about 257 adults with specific advanced cancers, including cervical, head and neck, esophageal, and a type o…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Major trial tests potential Game-Changer for common blood cancer
Disease control Recruiting nowThis large, global study is testing whether a new drug called surovatamig (AZD0486), when combined with the existing drug rituximab, works better and is safer than standard chemotherapy plus rituximab for people newly diagnosed with follicular lymphoma, a type of slow-growing blo…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Asthma Drug's Real-Life impact under the microscope
Disease control Recruiting nowThis study aims to see how well the approved biologic drug benralizumab works for people with severe asthma in their everyday lives, outside of a controlled clinical trial. It will follow 300 patients in Germany for a year, tracking their asthma symptoms, quality of life, lung fu…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Scientists test new weapon combo against tough lung cancer
Disease control Recruiting nowThis early-stage trial is testing the safety of combining a targeted drug (trastuzumab deruxtecan) with different immunotherapy drugs, with or without standard chemotherapy. It is for people with advanced non-small cell lung cancer that has a specific marker called HER2. The main…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Post-Approval watch: tracking a nerve tumor drug in real patients
Disease control Recruiting nowThis study is observing patients in Korea who are already taking Koselugo for neurofibromatosis type 1 (NF1) and its associated nerve tumors. Its main purpose is to monitor the drug's safety and see how well it works in everyday medical practice, outside of a controlled clinical …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Breakthrough trial targets Tough-to-Treat uterine cancer with precision drugs
Disease control Recruiting nowThis study compares new targeted drug combinations against standard chemotherapy for advanced or returning endometrial cancer. It will enroll 600 adults with specific tumor characteristics to see which approach better controls cancer growth and extends survival. Researchers are t…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for aggressive lung cancer: spanish trial tests promising drug
Disease control Recruiting nowThis study is testing the safety and effectiveness of the immunotherapy drug durvalumab for people in Spain with a specific, aggressive type of lung cancer called limited-stage small cell lung cancer. The drug is given after patients have completed standard chemotherapy and radia…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New pill targets Tough-to-Treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study is testing a new oral drug called AZD3632 for people with advanced blood cancers like leukemia and myelodysplastic syndromes that have returned or stopped responding to standard treatments. The main goals are to find a safe dose, see how the body processes …
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Heart-Safe cancer drug trial offers hope for vulnerable patients
Disease control Recruiting nowThis study is testing whether a leukemia drug called acalabrutinib is safe for people who also have moderate to severe heart problems. Researchers will compare it to other standard treatments to see which causes fewer heart-related side effects. The trial will enroll 60 adults wi…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Global study tests how well popular COPD treatment works in everyday life
Disease control Recruiting nowThis study follows 1,400 adults with moderate to severe COPD who are starting treatment with Breztri/Trixeo, a triple-therapy inhaler. Researchers will track how patients feel and function over 12 months in real-world medical settings across Latin America, Asia, and the Middle Ea…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Major trial tests promising new weapons against aggressive breast cancer
Disease control Recruiting nowThis large international study is testing whether new drug combinations work better than current standard treatments for advanced triple-negative breast cancer. Researchers will compare two experimental treatments against standard chemotherapy in 625 patients whose cancer has ret…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for lung cancer patients when standard drug fails
Disease control Recruiting nowThis study is for people with a specific type of advanced lung cancer (EGFR-mutated NSCLC) whose disease has gotten worse while taking the drug osimertinib. It will test whether a new drug called Dato-DXd, given alone or together with osimertinib, works better and is safer than s…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Tracking new hope for advanced uterine cancer patients
Disease control Recruiting nowThis study aims to collect real-world information on how well a specific combination of cancer drugs works for women with advanced or recurrent endometrial (uterine) cancer in Germany. It will follow 150 patients who are already receiving this standard treatment in their regular …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
AstraZeneca tests new combo drugs in fight against obesity
Disease control Recruiting nowThis study is testing two new investigational drugs, AZD6234 and AZD9550, to see if they are safe and can help with weight loss in Chinese adults who have obesity or are overweight. Researchers will give the drugs separately and together to about 871 participants to compare their…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Cancer drugs under watch: Real-World safety check begins
Disease control Recruiting nowThis study aims to monitor the safety and real-world effectiveness of two approved cancer drugs, durvalumab and olaparib, in patients with endometrial cancer in Korea. It will follow about 50 patients for up to a year after they start treatment as part of their normal medical car…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
First-in-Human trial launches: reprogrammed immune cells hunt deadly cancer mutations
Disease control Recruiting nowThis early-stage study is testing a new type of personalized cell therapy for adults with advanced solid tumors that have a specific genetic change called KRAS G12D. Doctors take a patient's own immune cells (T cells), genetically modify them in a lab to recognize and attack canc…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Global trial tests promising new treatment for Tough-to-Treat lung cancer
Disease control Recruiting nowThis global Phase 3 trial is testing whether a new drug called rilvegostomig works better than the current standard treatment when combined with chemotherapy for advanced squamous lung cancer. The study will involve about 880 patients whose cancer has spread and who haven't recei…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Drug safety under scrutiny for emergency bleeding treatment
Disease control Recruiting nowThis study aims to monitor the safety of a drug called Ondexxya, which is used in emergencies to reverse the effects of certain blood thinners in patients with life-threatening bleeding. It will enroll 300 patients who received the drug in real-world hospital settings. The main g…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
First human test for potential kidney disease treatment begins
Disease control Recruiting nowThis is the first study in people to test the safety of an experimental drug called AZD4248. Researchers will give single and multiple doses to healthy volunteers and people with diabetic kidney disease to see how the body handles it and check for side effects. A separate part of…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Approved breast cancer drug under Real-World watch in korea
Disease control Recruiting nowThis study monitors the safety and effectiveness of the already-approved breast cancer drug Capivasertib as it is used in everyday medical practice in South Korea. It aims to track any side effects and see how well the drug works for about 130 patients who are prescribed it accor…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New pill aims to tackle stubborn cholesterol
Disease control Recruiting nowThis study is testing a new oral medication called AZD0780 to see if it can safely and effectively lower 'bad' cholesterol (LDL-C) in people with dyslipidemia. The trial will involve about 360 adults in China, some already on standard cholesterol treatments and some not. Particip…
Phase: PHASE2, PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
AstraZeneca launches Multi-Drug attack on stomach cancer before surgery
Disease control Recruiting nowThis study is testing several new drug combinations given before and after surgery for people with advanced but removable stomach or esophageal cancer. The main goals are to see if these treatments are safe and if they can shrink or eliminate the tumor before it is surgically rem…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New cancer drug targets genetic weakness in advanced tumors
Disease control Recruiting nowThis early-stage study is testing a new drug called AZD3470 in people with advanced solid tumors that have a specific genetic flaw called MTAP deficiency. The main goals are to find a safe dose and see if the drug, given alone or with other cancer treatments, can help control the…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New drug combo challenges standard for Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is testing if a new combination of two immunotherapy drugs (durvalumab and tremelimumab) plus chemotherapy helps people with advanced non-small cell lung cancer live longer than the current standard treatment (pembrolizumab plus chemotherapy). It is specifically for pa…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Early test of new pill aims to zap bad cholesterol
Disease control Recruiting nowThis early-stage study is testing a new oral drug called AZD0780 to see if it is safe and can lower 'bad' cholesterol (LDL-C) levels. It will involve about 40 healthy adults who already have higher-than-ideal cholesterol. Participants will take either the drug or a placebo (a dum…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug combo aims to shrink advanced lung tumors
Disease control Recruiting nowThis study is testing whether a new drug called volrustomig, when given alongside standard chemotherapy, is safe and can help control advanced non-small cell lung cancer. It will involve about 180 people whose cancer has spread and who have not yet received treatment for the adva…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug trial offers hope before chemotherapy for Tough-to-Treat breast cancer
Disease control Recruiting nowThis study is testing an investigational drug called Dato-DXd for people with a specific type of advanced breast cancer that has spread and no longer responds to standard hormone treatments. The goal is to see if this drug, given as an IV infusion every 3 weeks, can effectively c…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
First patients test new brain cancer drug in race against time
Disease control Recruiting nowThis is the first study to give the experimental drug AZD1390 to people. It aims to find a safe dose of AZD1390 to give alongside standard radiation therapy for patients with aggressive brain tumors, including glioblastoma and cancer that has spread to the brain. The main goal is…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Asthma breakthrough? trial tests cutting daily meds for severe sufferers
Disease control Recruiting nowThis study is testing whether people with severe asthma who start taking the biologic drug tezepelumab can safely reduce or stop some of their other daily controller medications. It will enroll about 400 patients in China and follow them for a year. The main goal is to see if pat…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Korean study tracks approved liver cancer drugs in real patients
Disease control Recruiting nowThis study monitors the safety and effectiveness of two already-approved liver cancer drugs (Imjudo and Imfinzi) in real-world medical practice in Korea. It will follow 246 patients who are receiving these drugs as part of their standard cancer treatment. The goal is to collect i…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Major asthma study tests which rescue inhaler works better in real life
Disease control Recruiting nowThis study looks at how well two different asthma rescue inhalers work for preventing severe asthma attacks in everyday life. It will compare Airsupra against the commonly used albuterol by reviewing the medical records of 4,000 adults with asthma in the United States. The goal i…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New immune therapy trial offers hope for advanced liver cancer patients
Disease control Recruiting nowThis study is testing a new experimental drug called AZD9793 in adults with advanced liver cancer that has spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the treatment can shrink tumors. Researchers will give the drug to about 304 partic…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Gentler treatment tested for frail lymphoma patients
Disease control Recruiting nowThis study is testing a combination of two drugs, acalabrutinib and rituximab, for older or frail adults newly diagnosed with an aggressive type of lymphoma called DLBCL. The goal is to see if this treatment is safe and effective for patients who are too weak for standard, more i…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Major global trial tests new hope for millions with failing hearts and kidneys
Disease control Recruiting nowThis large, late-stage study aims to find out if a new two-in-one pill (balcinrenone/dapagliflozin) works better than a current standard drug (dapagliflozin) to prevent hospital visits and death from heart failure. It will involve about 4,800 adults worldwide who have both chroni…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for advanced colon cancer patients in global trial
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug (volrustomig) to standard chemotherapy works better for people with advanced colorectal cancer that hasn't spread to the liver. The trial will compare the safety and effectiveness of the new combination against standar…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
New drug trial aims to stop cervical cancer from coming back
Disease control Recruiting nowThis study is testing whether an investigational drug called volrustomig can help prevent cancer from returning in women with high-risk, locally advanced cervical cancer who have completed initial chemoradiation treatment. About 800 participants will be randomly assigned to recei…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
Major trial tests targeted therapy for aggressive digestive cancers
Disease control Recruiting nowThis large Phase 3 study is testing whether adding new targeted drugs to standard chemotherapy works better for people with advanced stomach, esophageal, or gastroesophageal junction cancers. The trial is specifically for patients whose cancers test positive for a protein called …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
First-in-Human trial launches for personalized Cancer-Killing cell therapy
Disease control Recruiting nowThis is a first-in-human study testing a new personalized cell therapy called NT-175. It is for adults with advanced solid cancers (like lung, colorectal, or breast cancer) that have spread and have a specific genetic mutation (TP53 R175H). The main goals are to find a safe dose …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for advanced lung cancer patients in global treatment trial
Disease control Recruiting nowThis global Phase 3 trial is testing whether a new drug called rilvegostomig works better than the standard drug pembrolizumab when both are combined with chemotherapy. It's for people with advanced non-small cell lung cancer that has spread and expresses a specific marker (PD-L1…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New immune therapy targets Hard-to-Treat digestive cancers
Disease control Recruiting nowThis early-stage trial is testing a new experimental drug called AZD5863 for people with advanced stomach, esophageal junction, esophageal, or pancreatic cancers that have spread. The study aims to find the safest dose and see if the treatment can shrink tumors. It's for adults w…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New 'Tumor-Agnostic' drug trial targets dozens of advanced cancers
Disease control Recruiting nowThis study is testing whether an existing cancer drug called T-DXd can help treat many different advanced cancers that have a specific protein marker called HER2. It will enroll about 468 adults with cancers like bladder, ovarian, pancreatic, and cervical cancer that have spread …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Can better training help control dangerous potassium in kidney patients?
Disease control Recruiting nowThis study aims to see if providing doctors and patients with better training and standardized care plans can improve how high potassium levels are managed in people with chronic kidney disease. It will enroll 1,000 adult patients in China who have kidney disease and high potassi…
Phase: NA • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug combo aims to keep advanced lung cancer at bay
Disease control Recruiting nowThis study is testing whether adding a new drug called domvanalimab to an existing immunotherapy (durvalumab) works better than durvalumab alone for people with advanced, inoperable lung cancer. The goal is to help control the cancer and prevent it from growing or spreading after…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New pill could stop breast Cancer's return in High-Risk patients
Disease control Recruiting nowThis large Phase 3 trial is testing whether a new oral medication called camizestrant works better than standard hormone therapy at preventing breast cancer from returning. The study involves 4,300 people with early-stage, hormone-positive breast cancer who have completed initial…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
First-of-its-Kind cell therapy trial launches for Tough-to-Treat MS
Disease control Recruiting nowThis early-stage study is testing a new personalized cell therapy called AZD0120 for adults with multiple sclerosis (MS) that has not responded well to other high-efficacy treatments. The main goal is to check the safety and side effects of the treatment and to find the best dose…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug trial offers hope for lymphoma patients out of options
Disease control Recruiting nowThis study is testing an experimental drug called surovatamig for adults whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior treatments. The main goals are to see if the drug can shrink the cancer and how safe it is for patients. Researcher…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for advanced stomach cancer patients in major drug trial
Disease control Recruiting nowThis study is testing several new combinations of cancer drugs for people with advanced stomach or gastroesophageal cancer that cannot be removed by surgery. The goal is to see if these combinations can shrink tumors, delay cancer growth, and are safe for patients. The trial is f…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Tracking a year of COPD care: does a triple therapy deliver?
Disease control Recruiting nowThis study looks back at data from real-world patients with moderate to severe COPD who started a triple-combination inhaler (BGF). It aims to see how their symptoms, quality of life, and number of flare-ups change over 12 months compared to before starting the treatment. The goa…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Scientists test 'Living Drug' to reboot immune system in autoimmune patients
Disease control Recruiting nowThis is an early-stage safety study testing a new type of personalized cell therapy called AZD0120. It aims to see if this treatment is safe and tolerable for adults with severe autoimmune diseases like systemic sclerosis, inflammatory myopathies, or difficult-to-treat rheumatoid…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New monthly shot aims to tame debilitating COPD attacks
Disease control Recruiting nowThis study is testing whether a monthly injection called tezepelumab can help control Chronic Obstructive Pulmonary Disease (COPD). It aims to reduce the frequency of serious breathing flare-ups and improve lung function and quality of life for adults with moderate to very severe…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New targeted drug enters human testing for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called AZD4360 in adults with advanced cancers of the stomach, pancreas, and related areas. The main goals are to find a safe dose and see if the drug shows any signs of helping to control the cancer. The drug is designed to target a s…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Major trial launches for advanced stomach cancer: new drug combo challenges standard treatment
Disease control Recruiting nowThis large Phase 3 trial is testing whether a new combination of cancer drugs works better than current standard treatment for advanced HER2-positive stomach cancer. The study will enroll 840 patients with previously untreated, advanced stomach or gastroesophageal junction cancer…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
Major heart study aims to stop heart failure before it starts
Disease control Recruiting nowThis large Phase 3 trial is testing whether adding a new drug called baxdrostat to an existing diabetes medication (dapagliflozin) can better prevent heart failure and heart-related death in people with type 2 diabetes who are at high risk. The study will enroll about 11,300 part…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New lupus drug study aims to tame disease and cut steroid dependence
Disease control Recruiting nowThis study is observing how well the drug anifrolumab works for people with systemic lupus in real-world Italian clinics. It aims to see if patients can achieve a state of very low disease activity while also reducing their daily steroid dose to 5mg or less. The study will follow…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New pill aims to tame COPD Flare-Ups in major global trial
Disease control Recruiting nowThis study is testing a new oral medication, AZD6793, to see if it can reduce the frequency and severity of symptom flare-ups (exacerbations) in people with moderate to very severe COPD. About 1160 participants will be randomly assigned to receive one of three different doses of …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Early trial tests simpler shot for advanced cancer treatment
Disease control Recruiting nowThis early-stage study is testing a new way to give the cancer drug rilvegostomig—as a simple injection under the skin instead of through an IV. It aims to find the right injection dose that gives similar drug levels in the body as the IV method and to check its safety. The study…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New injection aims to tame rare, debilitating muscle diseases
Disease control Recruiting nowThis study is testing whether adding a new injectable drug, anifrolumab, to standard treatment can better control disease activity in adults with polymyositis or dermatomyositis. It will involve about 240 participants who will receive either the drug or a placebo injection for a …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing a new drug called AZD0305 for people with multiple myeloma, a type of blood cancer, that has come back or stopped responding to at least three prior treatments. The main goals are to find a safe dose and see if the drug can help control the cancer, either by…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New drug duo aims to shield failing kidneys
Disease control Recruiting nowThis study is testing if adding a new drug called baxdrostat to an existing kidney-protecting drug (dapagliflozin) works better than baxdrostat alone. The goal is to see if the combination can better reduce protein in the urine, a key sign of kidney damage, in adults with chronic…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
Major trial aims to outperform standard lung cancer treatment
Disease control Recruiting nowThis study is testing whether new drug combinations work better than the current standard treatment for advanced non-small cell lung cancer. It will involve 675 people with a specific type of lung cancer that has spread and has high levels of a protein called PD-L1. Participants …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Global study tracks new lupus drug in everyday use
Disease control Recruiting nowThis study is observing how well the medication anifrolumab works for people with lupus when used in regular doctor's offices, not just in clinical trials. It will follow 200 patients across several countries for one year to see how their symptoms, skin problems, and quality of l…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New immune therapy targets advanced prostate cancer in early trial
Disease control Recruiting nowThis early-stage study is testing a new experimental drug called AZD6621 for men with metastatic prostate cancer that has stopped responding to standard treatments. The research will first find safe dose levels in a small group, then test those doses in more participants to see i…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New weapon tested in fight against advanced cancers
Disease control Recruiting nowThis study is testing a new, experimental cancer drug called AZD5335 to see if it is safe and if it can help control advanced cancers. It will be given alone and in combination with other cancer drugs to adults with ovarian, lung, or endometrial cancers that have progressed despi…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New hope for lymphoma patients as experimental drug trial begins
Disease control Recruiting nowThis early-stage study is testing a new antibody drug called AZD0486 in people with B-cell non-Hodgkin lymphoma that has returned or stopped responding to previous treatments. Researchers will give increasing doses to about 317 participants to find the safest amount and check for…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
New drug aims to stop viral lung infections from turning deadly
Disease control Recruiting nowThis study is testing an experimental drug called tozorakimab for people who are hospitalized with a serious viral lung infection and need extra oxygen. The main goal is to see if adding this drug to standard hospital care can help prevent patients from dying or needing a breathi…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for Tough-to-Treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study is testing a new drug called AZD0486, both alone and combined with other cancer treatments, for people with advanced B-cell blood cancers that have returned or stopped responding to prior therapies. It aims to find a safe dose and see if the drug can shrink…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Tracking a new lupus Drug's Real-World impact
Disease control Recruiting nowThis study aims to see how well the drug anifrolumab works for controlling lupus in real-world medical practice in Poland. It will follow 100 adult patients with lupus who are already receiving this medication through a national program for about 30 months. The main goal is to me…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for Tough-to-Treat leukemia: experimental drug enters human trials
Disease control Recruiting nowThis study is testing a new drug called AZD4512 for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or hasn't responded to other treatments. The main goals are to find a safe dose and see if the drug can help patients achieve remission. The study will e…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Breakthrough trial tests promising new combo for Tough-to-Treat breast cancer
Disease control Recruiting nowThis study is testing whether a new two-drug combination works better than current standard treatments for people with advanced breast cancer who have specific genetic mutations. It will involve about 500 adults whose cancer has spread and who have mutations in BRCA1, BRCA2, or P…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
First major trial for Kids' high potassium drug
Disease control Recruiting nowThis study is testing if a drug called sodium zirconium cyclosilicate (SZC), which is already used in adults, is safe and effective for treating high potassium levels in children. About 140 children under 18 will receive the drug, starting with older kids and moving to younger on…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New targeted drug trial opens for Tough-to-Treat digestive cancers
Disease control Recruiting nowThis study is testing an experimental drug called AZD0901, both by itself and combined with standard chemotherapy, for people with advanced cancers of the stomach, pancreas, and bile ducts. The main goals are to see if the treatment is safe and if it can shrink tumors. It is for …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope for lung cancer patients: drug study aims to keep cancer at bay
Disease control Recruiting nowThis study is observing how well a drug called durvalumab works to help control limited stage small-cell lung cancer after patients finish standard chemoradiation treatment. It will follow 200 patients in China who have not gotten worse after their initial treatment. The goal is …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Can a biologic drug put severe asthma into Long-Term remission?
Disease control Recruiting nowThis study aims to see if the biologic drug benralizumab can help people with severe eosinophilic asthma achieve and maintain clinical remission. It will follow 335 adult patients in Italy for up to two years to track their symptoms, lung function, and need for other medications.…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New pill targets tough blood cancers in early trial
Disease control Recruiting nowThis early-stage study is testing a new oral medication called AZD2962 for people with certain blood cancers that have returned or stopped responding to standard treatments. The main goal is to find a safe dose and see how the body handles the drug, while also looking for early s…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New asthma shot aims to tame severe attacks
Disease control Recruiting nowThis study is for people with a specific type of severe asthma (eosinophilic asthma) that isn't well-controlled on their current medium-dose inhaler. It compares two approaches: adding a new injectable medication (benralizumab) versus increasing the dose of the standard steroid i…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New immune drugs target tough liver cancers in major trial
Disease control Recruiting nowThis study is testing whether new immune-boosting drugs, given alone or with other cancer drugs, can help control advanced liver or bile duct cancer. It will enroll about 294 adults whose cancer has spread and is no longer responding to standard treatments. The main goals are to …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New asthma shot aims to tame severe attacks
Disease control Recruiting nowThis study is testing an investigational medicine called tozorakimab, given as an injection under the skin, for adults whose asthma is not well-controlled even with standard high-dose inhalers. The main goal is to see if different doses of tozorakimab can safely reduce the number…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Global race for better lung cancer treatment: new drug enters final testing phase
Disease control Recruiting nowThis large, late-stage study aims to see if a new immunotherapy drug called rilvegostomig works better than the current standard treatment (pembrolizumab) for people with advanced non-small cell lung cancer. It will enroll about 830 participants worldwide who have not yet receive…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New drug trial targets hormone disorder behind high blood pressure
Disease control Recruiting nowThis Phase 3 study is testing whether an investigational drug called baxdrostat can safely lower blood pressure and correct hormone imbalances in adults with primary aldosteronism, a condition where the adrenal glands produce too much aldosterone. Approximately 180 participants w…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Post-Approval watch: cancer Drug's safety under scrutiny in india
Disease control Recruiting nowThis study aims to monitor the safety of an already-approved breast cancer drug, trastuzumab deruxtecan, specifically in Indian patients. It will enroll 100 adults with advanced, HER2-positive breast cancer that has spread and who have already tried other HER2-targeted treatments…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New Gut-Healing drug enters Mid-Stage Crohn's trial
Disease control Recruiting nowThis study is testing an experimental drug called AZD7798 to see if it is safe and can help heal the inflamed gut lining in people with active Crohn's disease. It will involve about 30 participants who have an ileostomy, allowing doctors to directly see the drug's effects. For th…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New drug trial targets genetic cause of kidney failure
Disease control Recruiting nowThis study is testing an investigational drug called AZD2373 to see if it can slow kidney damage in people with a specific genetic form of kidney disease (APOL1-mediated). About 96 adults with the high-risk APOL1 genes will receive either the drug or a placebo for at least 30 wee…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New Two-Target drug enters human testing for Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is testing a new experimental drug called AZD2936 for people with advanced or metastatic non-small cell lung cancer. The main goals are to find a safe dose and see if the drug helps shrink tumors, especially in patients whose cancer has worsened after previous immunoth…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Asthma drug for kids under the microscope in new safety study
Disease control Recruiting nowThis study aims to monitor the safety and effectiveness of the asthma medication FASENRA in children aged 6 to 15 years. It will observe about 40 children with severe asthma who are starting FASENRA for the first time in real-world, everyday use. The main goal is to check for any…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Kids' acid reflux drug trial seeks to prevent painful relapse
Disease control Recruiting nowThis study aims to see if Nexium (esomeprazole) can safely keep erosive esophagitis healed in children aged 1 to 11. It will compare two different doses over 16 weeks to see which better prevents the painful stomach acid damage from returning. The goal is to provide ongoing contr…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
AstraZeneca tests 'Tumor-Targeting' radiation in advanced cancer patients
Disease control Recruiting nowThis is the first study in people for a new radioactive drug called [225Ac]-FPI-2068. It aims to find a safe dose and see how the drug travels in the body of 70 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check safety…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New asthma inhaler trial aims to cut severe attacks in half
Disease control Recruiting nowThis study is testing whether a combination inhaler (budesonide-albuterol) works better than a standard albuterol inhaler at preventing severe asthma attacks when used as needed. About 790 Chinese adults with symptomatic asthma who've had at least one severe attack in the past ye…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New hope for kids with rare blood and vessel diseases
Disease control Recruiting nowThis study is testing a drug called benralizumab in children aged 6 to 18 with rare diseases where high levels of a specific white blood cell (eosinophil) cause inflammation and damage. The main goals are to see if the drug is safe, how it behaves in the body, and if it can help …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Hospital training aims to close heart failure treatment gap
Disease control Recruiting nowThis study aims to see if training hospital doctors on the latest heart failure medication guidelines leads to better treatment for patients. It will observe about 438 patients with a specific type of heart failure to see if they receive the recommended drug combinations when lea…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Major trial aims to extend lives in advanced liver cancer
Disease control Recruiting nowThis large, late-stage trial is testing new drug combinations for people with advanced liver cancer that cannot be cured with surgery. It will compare two experimental combinations against a current standard treatment to see which helps patients live longer and control their canc…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Could a daily pill save thousands from heart attacks and strokes?
Disease control Recruiting nowThis large, late-stage study is testing whether a new oral drug called AZD0780 can prevent serious heart-related events like heart attacks, strokes, and death. It will involve over 15,000 adults who either already have heart disease or are at high risk for developing it. Particip…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New hope to stop Cancer's return after tough treatment
Disease control Recruiting nowThis large, global study is testing whether a new drug called volrustomig can help keep cancer from growing or spreading in people with advanced head and neck cancer who have just finished a standard course of chemotherapy and radiation. The trial will compare the drug to simply …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Breakthrough cell therapy trial offers hope for Tough-to-Treat blood cancer
Disease control Recruiting nowThis Phase 3 trial is testing whether a new, advanced cell therapy called AZD0120 works better than current standard drug combinations for people with multiple myeloma that has come back after treatment. The therapy involves modifying a patient's own immune cells to attack two sp…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Can a common COPD inhaler help the heart?
Disease control Recruiting nowThis study is testing whether a triple-combination inhaler (BGF) improves how well the heart and lungs work in people with COPD who have hyperinflated lungs. About 56 participants will try both the real inhaler and a placebo inhaler for short periods in a random order. The main g…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
New drug study aims to help people with debilitating muscle disease regain daily function
Disease control Recruiting nowThis study is observing how well the drug ravulizumab helps adults in Poland with generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness. Researchers will follow 50 patients for about 3 years to see if the treatment improves their ability to perform dai…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
New hope for tough stomach cancers: testing powerful drug combos
Disease control Recruiting nowThis study is testing whether a targeted cancer drug called T-DXd works better alone or when combined with chemotherapy and/or immunotherapy for advanced stomach and esophageal cancers that have a specific marker called HER2. It will involve about 450 adults with advanced cancer …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
New drug enters human testing for three debilitating autoimmune conditions
Disease control Recruiting nowThis early-stage study aims to test the safety and basic effects of a new experimental drug called AZD5492 in adults with lupus, inflammatory muscle diseases, or rheumatoid arthritis. Researchers will give participants one or two doses and closely monitor them for side effects an…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Recruiting nowThis study is testing a new cell therapy called AZD0120 for adults with severe systemic lupus that hasn't responded well to other treatments. The therapy involves modifying a patient's own immune cells to target and remove harmful cells that drive lupus. The first part of the stu…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New cancer pill trial offers hope for advanced tumors
Disease control Recruiting nowThis study is testing a new oral drug called AZD9574, both by itself and combined with other cancer therapies, in people with advanced solid tumors that have progressed. The main goals are to find safe doses and see early signs of whether the drug helps control the cancer. It wil…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
Global race for better mesothelioma treatment: new drug combo enters final testing phase
Disease control Recruiting nowThis large global study is testing whether adding an experimental drug called volrustomig to standard chemotherapy works better than current standard treatments for advanced pleural mesothelioma, a serious cancer often linked to asbestos exposure. About 825 adults with mesothelio…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New monthly shot aims to tame debilitating COPD attacks
Disease control Recruiting nowThis study is testing if a monthly injection called tezepelumab can help adults with moderate to very severe COPD. The main goal is to see if it reduces the number of times a person's breathing suddenly gets much worse (called an exacerbation or flare-up). About 990 participants …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 17, 2026 13:10 UTC
-
New drug trial targets Tough-to-Treat stomach cancers
Disease control Recruiting nowThis study is testing an experimental drug called AZD0901 for people with advanced stomach or gastroesophageal junction cancer that has spread and expresses a specific protein called CLDN18.2. It is for adults whose cancer has continued to grow after at least one prior treatment.…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC
-
New shot aims to tame dangerous asthma in kids
Disease control Recruiting nowThis study is testing an injectable medication called benralizumab in children and teenagers with a severe type of asthma. The goal is to see if it can safely reduce the number of serious asthma attacks (exacerbations) and improve daily symptoms. About 200 participants, aged 6 to…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 17, 2026 12:59 UTC
-
New drug trial offers hope for Tough-to-Treat leukemia
Disease control Recruiting nowThis study is testing an experimental drug called AZD0486 for adolescents and adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or hasn't responded to at least two prior treatments. The main goals are to find a safe and effective dose and to see if the dr…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
New Two-Pronged attack on deadly lung cancer enters final testing
Disease control Recruiting nowThis study is testing if a new two-drug combination works better than the current standard single drug for people with a specific type of advanced lung cancer. It will involve about 582 adults who have not yet received treatment for their advanced cancer. The main goal is to see …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
New hope for Tough-to-Treat lung cancer: phase 3 trial tests promising drug
Disease control Recruiting nowThis study is testing whether a new targeted drug called datopotamab deruxtecan works better than the standard chemotherapy (docetaxel) for people with advanced non-squamous lung cancer that has worsened after initial treatment. It will enroll 400 participants whose cancer tests …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC
-
First patients receive experimental injection for inherited heart disease
Disease control Recruiting nowThis is a first-in-human study to test the safety and how the body processes an experimental drug called AZD4063. It involves 31 adults with a specific genetic mutation that causes dilated cardiomyopathy, a condition where the heart muscle becomes weak. Participants will receive …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
Major trial aims to halt kidney failure and heart deaths
Disease control Recruiting nowThis large, late-stage study is testing whether adding a new drug called baxdrostat to an existing kidney-protective medicine (dapagliflozin) works better than the existing medicine alone. It aims to see if the combination can more effectively slow kidney damage, prevent kidney f…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
New hope for kids with severe lupus: major drug trial now recruiting
Disease control Recruiting nowThis study is testing an intravenous medication called anifrolumab in children and teenagers aged 5 to 17 who have moderate to severe systemic lupus erythematosus (lupus). Participants will receive either the study drug or a placebo (inactive solution) in addition to their standa…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
New hope for tough cancers: observing a promising Drug's Real-World impact
Disease control Recruiting nowThis study aims to see how well the drug T-DXd works in real-world settings for patients with advanced HER2-positive cancers who have already tried other treatments and have no good options left. It will follow about 100 patients with various solid tumors (excluding breast, lung,…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC
-
New cancer drug enters first human trials for Tough-to-Treat tumors
Disease control Recruiting nowThis is the first study in humans testing a new cancer drug called AZD9592. Researchers want to find safe doses and see if it helps control advanced cancers like lung, head/neck, and colorectal tumors. The study will test AZD9592 alone and combined with other cancer treatments in…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC
-
Scientists reprogram Patient's own cells to fight spreading prostate cancer
Disease control Recruiting nowThis study is testing a new treatment called AZD0754 for men whose prostate cancer has spread and is no longer responding to standard therapies. Doctors take a patient's own immune cells, modify them in a lab to target a protein on cancer cells, and then infuse them back into the…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC
-
New hope for tough cancers: first test of promising drug combo begins
Disease control Recruiting nowThis is the first study in people to test a new drug called AZD8421. It aims to find a safe dose and see if it can help control advanced breast cancer or ovarian cancer that has spread and stopped responding to standard treatments. The study will test AZD8421 by itself and combin…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC
-
New Two-Pronged cell therapy tested for blood cancer
Disease control Recruiting nowThis early-stage study is testing the safety and initial effects of a new cell therapy called AZD0120 in adults with multiple myeloma. The therapy involves modifying a patient's own immune cells to attack two targets on the cancer cells (BCMA and CD19). The main goal is to see ho…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC
-
New drug trial offers hope for stubborn skin lupus
Disease control Recruiting nowThis study is testing whether a drug called anifrolumab can help adults with chronic skin lupus who haven't gotten better with standard treatments. About 302 participants will receive either the drug or a placebo for 24 weeks, followed by an open period where everyone gets the dr…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
New drug targets root cause of rheumatoid arthritis pain
Disease control Recruiting nowThis study is testing a new drug called AZD1163 for people with moderate-to-severe rheumatoid arthritis (RA). It aims to see if the drug can safely reduce disease activity and inflammation when added to a person's current standard medications. About 320 participants will receive …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 09, 2026 14:23 UTC
-
New hope for Tough-to-Treat endometrial cancer: targeted drug enters major global trial
Disease control Recruiting nowThis large, late-stage trial is testing whether a new targeted drug called puxitatug samrotecan helps people with advanced endometrial cancer live longer or live longer without their cancer getting worse, compared to standard chemotherapy. It is for people whose cancer has contin…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 06, 2026 15:37 UTC
-
Three-Drug attack on Tough-to-Treat liver cancer
Disease control Recruiting nowThis study is testing a combination of three medicines—durvalumab, tremelimumab, and lenvatinib—as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this three-drug approach can better control the cancer's growth an…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC
-
New hope for lymphoma patients who have run out of options
Disease control Recruiting nowThis study is testing a new drug called AZD4512 for adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see if the drug helps control the cancer. It will involve about 91 par…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 02, 2026 15:25 UTC
-
First human test for new kidney disease drug begins
Disease control Recruiting nowThis is an early safety study for a new drug called AZD1613, designed for people with autosomal dominant polycystic kidney disease (ADPKD). The main goal is to see if the drug is safe and well-tolerated when given as an injection or through an IV, and to understand how the body p…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 02, 2026 15:24 UTC
-
New screening program aims to catch lung cancer earlier in smokers
Diagnosis Recruiting nowThis study is testing a new lung cancer screening program for current and former smokers. It will enroll 1000 people to get yearly low-dose CT scans and blood tests to see if cancer can be found earlier. The goal is to see if this screening approach works well in a public health …
Sponsor: AstraZeneca • Aim: Diagnosis
Last updated Apr 01, 2026 14:43 UTC
-
Could a simpler breath test revolutionize how we spot lung disease?
Diagnosis Recruiting nowThis study aims to see if two new, easier-to-perform breathing tests can help primary care doctors accurately diagnose asthma and COPD. It will involve 600 adults with symptoms but no prior diagnosis. The goal is to compare the accuracy of these new tests performed in a regular d…
Sponsor: AstraZeneca • Aim: Diagnosis
Last updated Mar 20, 2026 14:47 UTC
-
AI chatbot on WhatsApp aims to spot hidden breast cancer risk
Diagnosis Recruiting nowThis study is testing a new artificial intelligence (AI) tool designed to help identify women at high genetic risk for breast cancer. The tool, accessed via WhatsApp, asks women about their family history of cancer. Researchers will compare the AI's risk predictions to the result…
Sponsor: AstraZeneca • Aim: Diagnosis
Last updated Feb 27, 2026 15:18 UTC
-
One-Shot treatment aims to stop dangerous gut infection from coming back
Prevention Recruiting nowThis study is testing if a single dose of an investigational drug called AZD5148 can prevent a C. difficile infection (CDI) from coming back after initial treatment. About 230 adults who have recently been treated for a CDI will receive either AZD5148 or a placebo (inactive subst…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Prevention
Last updated Apr 01, 2026 14:42 UTC
-
New safety check for RSV protection in vulnerable babies
Prevention Recruiting nowThis study is checking the safety of a medicine called palivizumab that helps prevent severe RSV lung infections in high-risk children. It involves 138 Indian infants and toddlers under 2 years old who were born very early, have chronic lung disease, or have serious heart conditi…
Phase: NA • Sponsor: AstraZeneca • Aim: Prevention
Last updated Mar 30, 2026 14:31 UTC
-
New drug tested to shield vulnerable dialysis patients from dangerous infections
Prevention Recruiting nowThis study is testing a new drug called AZD7760 to see if it is safe and how it behaves in the body, with the goal of preventing Staphylococcus aureus (staph) infections. It will involve healthy volunteers and, importantly, people with end-stage kidney disease who receive dialysi…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Prevention
Last updated Mar 30, 2026 14:30 UTC
-
New drug trial aims to clear up severe sinus blockage
Symptom relief Recruiting nowThis study is testing if a medication called tezepelumab can improve symptoms for adults with severe chronic sinusitis and nasal polyps who are eligible for surgery. About 180 participants will receive the drug for 24 weeks to see if it reduces nasal congestion, improves smell, a…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Symptom relief
Last updated Mar 27, 2026 12:41 UTC
-
Does this leukemia pill let patients live a normal life?
Symptom relief Recruiting nowThis study aims to understand how a drug called acalabrutinib affects the daily life and well-being of people with chronic lymphocytic leukemia (CLL). Researchers will look back at health records and quality-of-life surveys from about 120 patients in France over the first year of…
Sponsor: AstraZeneca • Aim: Symptom relief
Last updated Mar 27, 2026 12:40 UTC
-
Massive study launches to map Russia's COPD landscape
Knowledge-focused Recruiting nowThis study aims to better understand people with chronic obstructive pulmonary disease (COPD) in Russia. Researchers will observe 2000 patients with moderate-to-severe COPD who experience frequent symptom flare-ups. The goal is to describe who these patients are and see what trea…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 19:56 UTC
-
Scientists seek clues to rising lung disease in china
Knowledge-focused Recruiting nowThis study aims to better understand a chronic lung disease called non-cystic fibrosis bronchiectasis (NCFBE) in Chinese patients. Researchers will observe 320 participants, including people with the disease and healthy volunteers, to identify patterns in their symptoms and biolo…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 19:56 UTC
-
Doctors' lung cancer treatment choices under the microscope in major brazilian study
Knowledge-focused Recruiting nowThis study aims to understand how doctors in Brazil treat advanced non-small cell lung cancer in real-world settings. Researchers will collect medical records from 200 patients and survey about 300 oncologists to see what treatments they choose and whether they follow national gu…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:43 UTC
-
Cancer Drug's Real-World effectiveness put to the test
Knowledge-focused Recruiting nowThis study compares how well the cancer drug T-DXd works compared to standard treatments for patients with advanced HER2-positive solid tumors. Researchers will analyze existing medical records from about 105 patients who received either T-DXd in previous trials or standard care …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:43 UTC
-
Spanish researchers dig through medical records to see how kidney drug performs in real life
Knowledge-focused Recruiting nowThis study looks back at existing medical records to understand how dapagliflozin, a medication already approved for chronic kidney disease, is used and how well it works in routine Spanish healthcare. Researchers will analyze data from over 14,000 patients to see how the drug af…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Massive 35,000-Patient study launches to map Real-World care for chronic diseases
Knowledge-focused Recruiting nowThis large observational study aims to collect real-world information on how patients with type 2 diabetes, high blood pressure, heart failure, and/or chronic kidney disease are currently managed. It will enroll 35,000 adults from many countries to track their treatments, doctor …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Massive asthma study launches to map Russia's uncontrolled cases
Knowledge-focused Recruiting nowThis study is creating a large registry to collect information about adults with uncontrolled asthma across Russia. It will observe 9,000 patients receiving standard care (excluding newer biologic drugs) to better understand who is affected, how they are treated, and their health…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Doctors track new asthma Drug's Real-World impact
Knowledge-focused Recruiting nowThis study aims to learn more about patients with severe asthma who are prescribed the biologic drug tezepelumab in real-world Italian clinics. It will follow 300 patients for up to two years to see how the treatment affects their asthma attacks, symptoms, lung function, and over…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
Scientists launch major study to map COPD's hidden patterns
Knowledge-focused Recruiting nowThis observational study aims to better understand Chronic Obstructive Pulmonary Disease (COPD) in Chinese patients. Researchers will follow 850 participants with COPD or early signs of the disease for 1-3 years, collecting health data, lung function tests, and blood samples. The…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
Could new weight loss shots make your birth control less effective?
Knowledge-focused Recruiting nowThis study aims to see if new weight loss injections (AZD6234 and AZD9550) change how the body processes birth control pills. It will involve 75 healthy women with overweight or obesity. Researchers will measure drug levels in the blood to check for interactions and monitor safet…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
Researchers track lupus drug in breast milk to protect babies
Knowledge-focused Recruiting nowThis study aims to understand how much of the lupus medication anifrolumab passes into breast milk and reaches nursing infants. It will enroll 16 breastfeeding mothers who are already taking this drug for their lupus. Researchers will collect breast milk and blood samples from mo…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
Major study tracks cancer and infection risks in lupus treatment
Knowledge-focused Recruiting nowThis study is monitoring the safety of the lupus medication anifrolumab by comparing patients who take it against similar patients who receive standard treatments. Researchers will track whether patients develop serious infections or cancers over time. The study is observational,…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
AI steps into the lab: can computers help doctors spot cancer faster?
Knowledge-focused Recruiting nowThis study is testing whether new computer programs (AI algorithms) can help pathologists diagnose lung and breast cancer more quickly and accurately. Researchers will look back at samples from 600 patients in four countries to see how AI compares to standard lab methods. The goa…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
First human test for mystery drug begins
Knowledge-focused Recruiting nowThis is the first time a new drug called AZD3974 is being given to people. The main goal is to check if it is safe and to see how the body absorbs and removes it. The study will involve 176 healthy volunteers, including people of Japanese and Chinese descent. Some participants wi…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
Cancer drug tested in people with liver issues
Knowledge-focused Recruiting nowThis study aims to understand how a single dose of the cancer drug capivasertib is processed by the body in people with moderate liver problems. It will compare 20 participants with liver impairment to a control group with normal liver function. The main goal is to check if the d…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
French doctors track Real-World results of prostate cancer drug
Knowledge-focused Recruiting nowThis study is observing 300 men in France with advanced prostate cancer who are taking the medication olaparib in real-world settings. Researchers will track how long patients stay on the treatment, how well it works, and what side effects occur. The goal is to gather practical i…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
Massive global study tracks Real-World results of new liver cancer treatments
Knowledge-focused Recruiting nowThis study aims to understand how well durvalumab-based treatments work for liver and bile duct cancers in real-world medical settings, outside of controlled clinical trials. Researchers will follow approximately 4,490 patients across 22 countries who are already receiving these …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:10 UTC
-
First look: tracking babies born to moms on rare disease drug
Knowledge-focused Recruiting nowThis study aims to understand the safety of the medication eplontersen during pregnancy and breastfeeding for people with a rare disease called transthyretin amyloidosis. Researchers will collect and review information from medical reports on pregnant or breastfeeding individuals…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:35 UTC
-
Researchers map the hidden toll of a devastating rare disease
Knowledge-focused Recruiting nowThis study aims to understand the real-world impact of a rare and serious kidney disease called atypical hemolytic uremic syndrome (aHUS) in Egypt. Researchers will look back at the medical records of up to 200 patients diagnosed over the past 14 years to describe their symptoms,…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Tracking Real-World survival for new lung cancer treatment
Knowledge-focused Recruiting nowThis study aims to collect real-world information on how well a specific combination of immunotherapy and chemotherapy drugs works for patients with advanced non-squamous lung cancer. It will follow 600 patients in Germany who are already scheduled to receive this treatment, focu…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Massive study tracks 3000 kidney patients to uncover best treatments
Knowledge-focused Recruiting nowThis study aims to collect real-world information on how chronic kidney disease (CKD) is managed in China and what happens to patients over time. It will follow 3,000 adults with CKD for nearly two years, observing their treatments and health outcomes. The goal is to better under…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Mapping the Real-World impact of a complex genetic disorder
Knowledge-focused Recruiting nowThis study aims to gather detailed information about adults living with neurofibromatosis type 1 (NF1) in Russia. Researchers will observe 200 patients in their regular care settings to document their symptoms, tumor characteristics, overall health, and quality of life. The goal …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Tracking real results: how men fare on advanced prostate cancer combo
Knowledge-focused Recruiting nowThis study observes 250 men with advanced prostate cancer who are already receiving a specific two-drug combination (olaparib + abiraterone) in real-world clinics. The goal is to understand how long patients stay on this treatment and what happens afterward, without changing thei…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC
-
Massive 52,000-Patient study maps the hidden journey of a rare heart and nerve disease
Knowledge-focused Recruiting nowThis study aims to understand the real-world experience of people with ATTR amyloidosis, a rare disease that affects the heart and nerves. Researchers will analyze existing health records of over 52,000 patients to learn about their symptoms, treatments, quality of life, and heal…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC
-
Doctors track Real-World lung cancer care in major russian hospitals
Knowledge-focused Recruiting nowThis study aims to understand how doctors in Russia currently treat patients with advanced lung cancer that cannot be surgically removed. Researchers will observe the treatment patterns and short-term outcomes for 2,000 patients receiving combined chemotherapy and radiation acros…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC
-
Kids test two asthma inhalers in small safety study
Knowledge-focused Recruiting nowThis study aims to understand how two different asthma inhaler devices deliver medication into children's bodies. It will enroll 12 children aged 4-12 with asthma to compare how much medicine gets into their bloodstream from each device. This is an early safety study that measure…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC
-
Researchers map genetic landscape of aggressive uterine cancer
Knowledge-focused Recruiting nowThis study aims to collect real-world information about patients with advanced endometrial cancer in Russia. Researchers will analyze tumor samples from 500 patients to understand specific genetic and molecular characteristics. The study will also document what first-line treatme…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC
-
Doctors track Real-Life results of leukemia drug in belarus
Knowledge-focused Recruiting nowThis study aims to understand how well the drug acalabrutinib works for treating chronic lymphocytic leukemia (CLL) in everyday medical practice in Belarus. Researchers will observe about 50 adult patients who have just started taking this medication and follow them for two years…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:31 UTC
-
Major study probes potential cancer link to popular diabetes drug
Knowledge-focused Recruiting nowThis study aims to find out if a diabetes medication called exenatide increases the risk of pancreatic cancer compared to other diabetes drugs. Researchers will analyze the health records of 24,000 type 2 diabetes patients across Europe from 2006 to 2023. The study is observation…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:31 UTC
-
What do patients and doctors really want from lung cancer drugs?
Knowledge-focused Recruiting nowThis study aims to understand what matters most to patients and doctors when choosing first-line treatments for advanced lung cancer. Researchers will survey 590 Chinese patients and physicians who have experience with these treatments. The survey asks participants to make choice…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
Massive study maps lung Cancer's Real-World impact in canada
Knowledge-focused Recruiting nowThis study aims to understand how lung cancer is treated and what it costs the healthcare system in Canada. Researchers will analyze existing health records from 60,000 patients in Alberta and Ontario to see what treatments were used, how long patients lived, and the associated h…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
First human tests: does kidney health change how a new drug works?
Knowledge-focused Recruiting nowThis early-stage study aims to understand how a new drug, opemalirsen, is processed by the body in people with different levels of kidney function compared to people with normal kidney function. About 50 adults, some with kidney impairment and some without, will receive a single …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
Mapping the fight: how russia treats advanced prostate cancer
Knowledge-focused Recruiting nowThis study aims to understand how doctors in Russia treat men with a newly diagnosed, aggressive form of prostate cancer that has already spread. Researchers will observe 400 patients to see what treatments they receive and will test their stored tumor samples for specific biolog…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
Scientists trace cancer Drug's journey through patients
Knowledge-focused Recruiting nowThis early study aims to understand how a new cancer drug called Saruparib is absorbed, distributed, and eliminated by the body. It will enroll 8 patients with advanced solid tumors who have run out of standard treatment options. Researchers will track the drug using special mark…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
Massive global study tracks rare heart and nerve disease
Knowledge-focused Recruiting nowThis study aims to observe and document the real-world experiences of people living with ATTR amyloidosis, a rare disease that can damage the heart and nerves. It will follow at least 1850 patients for 3 to 7 years, collecting information from their regular medical visits to unde…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC
-
Tracking baby health: lupus drug pregnancy registry launches
Knowledge-focused Recruiting nowThis study is collecting information about pregnancy outcomes in women with moderate to severe lupus who take the medication anifrolumab. Researchers will compare health results for mothers and babies exposed to the drug during pregnancy against those who used other lupus treatme…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC
-
Scientists test new Pill's journey through the body
Knowledge-focused Recruiting nowThis early-stage study aims to understand how the body absorbs and processes different pill versions of an experimental drug called AZD5004. It will involve 64 healthy volunteers who will take single doses of different pill formulations. Researchers will measure drug levels in th…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC
-
Brazil launches major study to map the Real-World journey of severe lung disease patients
Knowledge-focused Recruiting nowThis study aims to understand what happens to people in Brazil with severe and very severe COPD over one year. It will follow 693 patients from hospitals across the country, tracking how often they are hospitalized, have symptom flare-ups, or pass away. The goal is to gather real…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC
-
Tracking 800 breast cancer Patients' Real-Life treatment journey
Knowledge-focused Recruiting nowThis study observes how patients with advanced breast cancer respond to an existing medication called trastuzumab deruxtecan in real-world settings. Researchers will track 800 patients in Germany to understand how long the treatment works before patients need new therapy and how …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:27 UTC
-
First human tests begin for new heart drug candidate
Knowledge-focused Recruiting nowThis is a very early, first-in-human study to check if a new drug called AZD4954 is safe and how it behaves in the body. It will test single and multiple doses in healthy volunteers and people with high cholesterol who also have a specific risk factor called elevated Lp(a). The m…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:41 UTC
-
Scientists use High-Tech scans to track new liver drug
Knowledge-focused Recruiting nowThis early-stage study aims to see if an experimental oral drug, AZD2389, reaches and engages its intended target in the livers of people with advanced liver scarring (fibrosis). Researchers will use special PET scans to measure this in about 12 participants. The main goal is to …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:40 UTC
-
UK researchers track Real-World results of leukemia drug
Knowledge-focused Recruiting nowThis study is collecting information on how well the drug acalabrutinib works for patients with chronic lymphocytic leukemia (CLL) in real-world UK clinics. It will look back at the medical records of about 350 adults who started this treatment through a special early access prog…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:39 UTC
-
Massive study launched to check if asthma drug affects heart health
Knowledge-focused Recruiting nowThis study is checking if the severe asthma medication tezepelumab increases the risk of serious heart problems like heart attacks or strokes. It will follow over 16,000 teens and adults with severe asthma in four countries, comparing those taking the drug to those on standard tr…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:39 UTC
-
Massive 5,000-Person snapshot of Russia's severe asthma patients
Knowledge-focused Recruiting nowThis study aims to gather detailed information about adults in Russia who have severe asthma that remains uncontrolled despite standard treatments. It will observe 5,000 patients across many regions to understand their health profiles, current medications, and how the disease aff…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:39 UTC
-
Researchers map Russia's bladder cancer care landscape
Knowledge-focused Recruiting nowThis study aims to understand how bladder cancer is currently treated in Russia and how often certain biomarkers (HER2 and PD-L1) are present in tumors. It will observe 600 adult patients with different stages of bladder cancer during a single routine visit. The study does not te…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC
-
Tracking babies born to moms on lupus drug
Knowledge-focused Recruiting nowThis study aims to understand the safety of the lupus medication anifrolumab during pregnancy. It will follow about 240 women with lupus who took the drug while pregnant, tracking their health and their babies' health for up to a year after birth. The main goal is to check for an…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:09 UTC
-
Heart and lung health linked: major study seeks answers
Knowledge-focused Recruiting nowThis study aims to find out how many people with heart disease also have a lung condition called COPD. It will follow 3000 adults with heart conditions to see if a coordinated approach to managing both heart and lung health can reduce hospital visits and improve quality of life. …
Phase: NA • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:08 UTC
-
Scientists map how breast cancer evolves during treatment
Knowledge-focused Recruiting nowThis study aims to understand how the genetic makeup of advanced breast cancer changes as patients receive treatment. Researchers will compare blood tests from 70 patients before and after therapy to see if new mutations emerge. The goal is to gather knowledge that may help guide…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:08 UTC
-
Early diabetes drug test: does new pill change how metformin works?
Knowledge-focused Recruiting nowThis early-stage study aims to understand how a new investigational drug, AZD6793, interacts with the common diabetes medication metformin. It will involve about 28 people with type 2 diabetes who are already taking metformin. The main goal is to see if AZD6793 changes how the bo…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:07 UTC
-
Tracking lung cancer drugs in real patients
Knowledge-focused Recruiting nowThis study observes how approved AstraZeneca lung cancer drugs work in real-world settings, not testing new treatments. It will follow 300 patients with non-small cell lung cancer who are already receiving these drugs as part of their standard care. Researchers will track how lon…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:07 UTC
-
Brazil launches major study to map ovarian cancer treatment and survival
Knowledge-focused Recruiting nowThis study aims to understand how ovarian cancer is currently treated in Brazil and what outcomes patients experience. It will follow 250 patients for three years to collect information on their treatments, disease progression, and survival. The goal is to identify strengths and …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:02 UTC
-
Scientists test if breakfast changes how your body uses a new pill
Knowledge-focused Recruiting nowThis early study aims to understand how eating a meal affects the way the body absorbs and processes a new combination pill containing two drugs, zibotentan and dapagliflozin. It involves 26 healthy volunteers who will take the pill once on an empty stomach and once after a high-…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:02 UTC
-
Tracking Real-World cancer care: how russia treats its toughest prostate cases
Knowledge-focused Recruiting nowThis study aims to understand how doctors in Russia treat men with aggressive, spreading prostate cancer that is still sensitive to hormone therapy. Researchers will observe 400 patients to see what treatments they receive in real-world practice and compare genetic test results f…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:02 UTC
-
First human tests begin for mystery drug AZD1613
Knowledge-focused Recruiting nowThis is the first study in people for a new drug called AZD1613, made by AstraZeneca. It aims to check if the drug is safe, how the body handles it, and what it does in healthy volunteers, including people of Chinese and Japanese descent. The study will give the drug at different…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:02 UTC
-
French study tracks Real-World breast cancer treatment patterns
Knowledge-focused Recruiting nowThis French study observes breast cancer patients taking a medication called olaparib for 12 months in real-world settings. Researchers want to see how many patients complete the full treatment course and understand factors that might affect completion. The study collects informa…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:29 UTC
-
Scientists map the hidden journey of a rare bone disease
Knowledge-focused Recruiting nowThis study aims to better understand how a specific genetic change affects the symptoms and progression of hypophosphatasia (HPP), a rare bone and mineral disorder. Researchers will observe 55 children and adults in Russia who have this genetic variant but are not receiving speci…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:19 UTC
-
Brazilian lung cancer treatment patterns revealed in major review
Knowledge-focused Recruiting nowThis study looks back at medical records of 250 Brazilian patients with advanced non-squamous lung cancer whose initial chemotherapy stopped working. Researchers will examine what treatments these patients received next and how they responded. The goal is to understand real-world…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:19 UTC
-
Scientists test new drug combo in prostate cancer before surgery
Knowledge-focused Recruiting nowThis study aims to understand the biological effects of two investigational drugs, saruparib and darolutamide, given alone and in combination to men newly diagnosed with prostate cancer who are scheduled for surgery. The main goal is to see how these treatments change specific ma…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:18 UTC
-
Doctors track 450 patients to map Real-World MG care
Knowledge-focused Recruiting nowThis study aims to understand how doctors in Russia currently treat adults with a specific form of myasthenia gravis (gMG) in everyday practice. It will observe 450 patients over three years, collecting information from their medical records about the treatments they receive and …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:16 UTC
-
Moscow COPD patients under the microscope in major health survey
Knowledge-focused Recruiting nowThis study aims to gather detailed information about people with Chronic Obstructive Pulmonary Disease (COPD) in Moscow who experience frequent symptom flare-ups. Researchers will observe 500 patients over time to understand their health characteristics, current treatments, and r…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:41 UTC
-
Scientists Fine-Tune emergency bleeding drug in healthy volunteers
Knowledge-focused Recruiting nowThis early-stage study aims to better understand how andexanet, a drug used to reverse the effects of certain blood thinners in emergencies, works and when it's safe to give another blood thinner (enoxaparin) afterward. It involves 186 healthy participants and will measure how th…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:41 UTC
-
Egypt's first major NF1 registry launches to map rare genetic disorder
Knowledge-focused Recruiting nowThis study aims to understand how Neurofibromatosis Type 1 (NF1) affects people in Egypt by collecting health information from 200 patients diagnosed between 2010 and 2023. Researchers will track how the disease progresses over time, what treatments patients receive, and how comm…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 17, 2026 13:09 UTC
-
Scientists test common Drug's impact on experimental cancer therapy
Knowledge-focused Recruiting nowThis early-phase study aims to understand how a common antifungal medication (itraconazole) affects the levels of a new, experimental cancer drug (AZD5335) in the body. It involves about 24 participants with recurrent ovarian, fallopian tube, or primary peritoneal cancer. The mai…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:26 UTC
-
Heart doctors screen smokers for hidden lung disease
Knowledge-focused Recruiting nowThis study aims to find out how many smokers visiting heart clinics also have undiagnosed COPD, a serious lung disease. Researchers will enroll 1,000 adult smokers at cardiology clinics to perform breathing tests and questionnaires. The goal is to better understand the link betwe…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:25 UTC
-
Scientists map asthma in chinese population to pave way for tailored therapies
Knowledge-focused Recruiting nowThis study aims to better understand asthma in Chinese adults by observing their disease characteristics, current treatments, and biological markers. Researchers will collect data from 355 participants to identify different types of asthma and how they respond to care. The goal i…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 09, 2026 14:23 UTC
-
Massive study aims to find hidden kidney disease in high blood pressure patients
Knowledge-focused Recruiting nowThis study aims to understand how often people with high blood pressure who show early signs of kidney damage actually get diagnosed with chronic kidney disease (CKD) in Kazakhstan. Researchers will observe over 1,200 adult patients with high blood pressure and specific lab marke…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 05, 2026 14:00 UTC
-
Tracking 750 Women's journeys to understand ovarian cancer care
Knowledge-focused Recruiting nowThis study aims to understand how ovarian cancer treatments work in real-world medical practice in Germany. It will follow 750 women with newly diagnosed advanced ovarian cancer who are receiving standard chemotherapy and may get additional maintenance therapy. Researchers will t…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 02, 2026 15:21 UTC
-
A multicenter real-world observational study of the prevalence, diagnostic pathways, and clinical characteristics of lysosomal acid lipase deficiency in pediatric and adolescent risk groups in the russian federation (HELIOS)
Recruiting nowA multicenter real-world observational study of the prevalence, diagnostic pathways, and clinical characteristics of lysosomal acid lipase deficiency in pediatric and adolescent risk groups in the Russian Federation (HELIOS)
Sponsor: AstraZeneca
Last updated Mar 20, 2026 14:48 UTC